{"filing":{"accession_number":"0001193125-26-407823","cik":"0001681087","ticker":"TECX","company_name":"Tectonic Therapeutic, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"d20857d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1681087/000119312526407823/d20857d8k.htm"},"events":[{"id":35841,"run_id":33031,"accession_number":"0001193125-26-407823","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Tectonic announced favorable Phase 1a safety and tolerability results for TX2100, along with FDA Fast Track designation and IND clearance for Phase 1b trials. This is a material clinical development milestone for a clinical-stage biotech company, representing significant progress in drug development. While not a traditional earnings release (the company is pre-revenue), the clinical trial results and regulatory approvals are operationally significant events that would affect investor assessment of the company's pipeline and development trajectory.","company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":40037,"accession_number":"0001193125-26-407823","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tectonic announced favorable Phase 1a safety and tolerability results for TX2100, along with FDA Fast Track designation and IND clearance for Phase 1b trials. This is a material clinical development milestone for a clinical-stage biotech company, representing significant progress in drug development. While not a traditional earnings release (the company is pre-revenue), the clinical trial results and regulatory approvals are operationally significant events that would affect investor assessment of the company's pipeline and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T21:20:13.296206+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40037,"accession_number":"0001193125-26-407823","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tectonic announced favorable Phase 1a safety and tolerability results for TX2100, along with FDA Fast Track designation and IND clearance for Phase 1b trials. This is a material clinical development milestone for a clinical-stage biotech company, representing significant progress in drug development. While not a traditional earnings release (the company is pre-revenue), the clinical trial results and regulatory approvals are operationally significant events that would affect investor assessment of the company's pipeline and development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T21:20:13.296206+00:00","company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","filing_date":"2026-09-29"}]}